Medivolve Inc.

Medivolve, Inc. engages in seeking technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate risk-adjusted returns for investors. It offers investors a diversified investment in the COVID-19 medical space across the following areas; prevention, detection, and treatment. The company was founded on November 8, 2005 and is headquartered in Toronto, Canada.

The Global Coronavirus Diagnostic Market Could Grow From $19.4 Billion in 2020 to $23.7 Billion by 2027 at a CAGR of 2.9%. As the Coronavirus Pandemic Continues to Devastate Countries and Threaten Lives with New Deadly Variants, Mass-Testing will be Critical in Ensuring Public Health Safety.

Medivolve (NEO:MEDV) (OTCMKTS:COPRF) has a Business Strategy to Lead

• Medivolve recently pivoted to COVID testing. It is headed by a veteran of the healthcare industry with a proven track record of success.
• The global coronavirus testing market is massive and forecasted to grow even more significantly. In 2020 the market was $19.4 billion and expected to grow at a 2.9% CAGR to $23.7 billion in 2027.
• The company is building out its testing infrastructure through wholly-owned subsidiary Collection Sites. The company’s mobile testing sites are a safe, convenient, and accessible way to get tested for COVID-19.
• Medivolve’s mobile diagnostic sites are very economical and efficient. On aggregate, the company has conducted approximately 74,000 tests in January across 35 operating sites.
• The company isn’t tied to any particular technology; therefore, it can offer the latest disruptive technology or groundbreaking innovation. The company’s diagnostic sites currently offer three types of COVID tests: antibody, antigen, and RT PCR tests.
• The company has partnered up with some big-name companies in the real estate industry, such as the Simon Property Group.
• Looking beyond COVID, the Collection Sites could be converted to test and treat a whole host of other diseases. Furthermore, as these sites remain operational, Medivolve is building an incredibly robust client list of more than 100,000 patient names.
• The stock formed a strong base in the five months of July 2020 to November 2020, as the stock price consolidated from $0.10 to $0.20. It has rallied since then, rewarding investors with more than 500% returns. Looking at the technical indicators, the latest pullback could be an attractive entry point.

http://fast.wistia.net/embed/iframe/qlgn6z93fn

The rollout of coronavirus testing and vaccines is proving to be one of the greatest logistical challenges of our time. Despite the existence of vaccines to fight against the coronavirus, it is still essential to set up the necessary infrastructure for mass testing. There is evidence suggesting that the current vaccines are effective at stopping the latest mutations of the coronavirus. However, as new variants emerge, it is vital to have the necessary mass testing infrastructure to prevent another outbreak.

In 2020 the global coronavirus diagnostic market was valued at $19.4 billion and expected to grow at a 5-year CAGR of 2.9%. Coronavirus testing plays a critical role in containing the spread of infection and ensuring a safe reopening of the economy. Rising government initiatives are expected to fuel the implementation of mass testing programs. Currently, the majority of government resources are being shifted from testing to vaccine deployment. For example, in Los Angeles and New York, the large stadiums used as testing centers are being transitioned to vaccination sites. Medivolve (NEO:MEDV, OTCMKTS:COPRF) has a business that could take advantage of the situation, ensuring that mass testing continues to be available.

“We’ve gone from 1 million to 4.5 million tests per week in the U.S., but we’ll need to redouble our efforts to make it to 30 million tests per week and beyond to reopen communities and economies and keep them open.”

— The Rockefeller Foundation

CEO Interview

http://fast.wistia.net/embed/iframe/hxz3ovklke

Who is Medivolve (NEO:MEDV) (OTCMKTS:COPRF)?

Medivolve started as an investment company focusing on verticals such as climate, technology, and healthcare. In recent times due to the coronavirus pandemic, Medivolve has pivoted to 100% focus on healthcare, specifically the battle against the coronavirus. One of the first initiatives the company was involved with was on the logistics side to safely set up events during COVID and designing protocols around that. The company’s projects included COVID testing in Colombia and setting up the health bubble to film the popular series “Shark Week.”

Since then, the company has been building out the infrastructure to fight against the coronavirus, particularly in the verticals of detection, prevention, and treatment. The company has built lightweight, mobile, and flexible coronavirus diagnostic sites that can be deployed quickly and cheaply. The company has rolled out this initiative via its wholly-owned subsidiary, “Collection Sites.” These diagnostic centers carry the “Collection Sites” brand and are a safe, convenient and accessible way to get tested for COVID-19.

Medivolve’s Collection Sites are a Cost-Effective Solution

The company’s mobile diagnostic sites are very economical and efficient. On aggregate, the company has conducted approximately 74,000 tests in January across 35 operating sites. These testing sites are typically open 10 hours a day and can do a maximum of 15 tests per hour. So each cube potentially could do 150 tests in a single day, which indicates that these sites are operationally efficient and are well-equipped to handle any amount of sudden influx. This last point is crucial due to the exponential spread of an infectious disease like the coronavirus.

Medivolve offers various COVID tests at an average price of $96 per test, with tests as low as $60 per test. According to a Peterson KFF Health study, 1 in 5 COVID tests cost more than $200. Therefore Collection Sites’ one-stop mobile site provides an affordable solution to this cost issue.

The company isn’t tied to any particular technology. Therefore, it can offer the latest disruptive technology or groundbreaking innovation. The company’s diagnostic sites currently offer three types of COVID tests: antibody, antigen, and RT PCR tests.

The Rapid Antibody test is done via a blood sample, and immediate results can be provided. The test looks for COVID antibodies in the blood to determine if there was a past infection. These results are sent to the lab for certification. The RT PCR test and Antigen tests are done via a nasal or throat swab taken by a healthcare provider. This reaction test looks for genetic material to determine if the person has an active COVID infection. These swab results are then sent to a lab for testing.

Medivolve Poised for Rapid Expansion

The company is in rapid expansion and could soon be rolling out hundreds of these testing sites. The company has partnered up with some big-name companies in the real estate industry, such as the Simon Property Group (NYSE: SPG). Just a brief background on each of these companies show the scale of Medivolve’s potential rollout.

• Simon Property Group is a real estate investment trust engaged and arguably the largest mall operator in North America. The company owns an assortment of premier shopping, dining, entertainment, and mixed-use destinations. The company provides community gathering places for millions of people every day. Medivolve is installing Collection Sites in 165 of the company’s locations.

Investor Presentation

These sites can be set up quickly and take up a minimal footprint (typically 100 square feet). Medivolve pays weekly for space, and these are insured with no liability to the retailer. The company has partnered with Alcala Labs to handle all the testing. Alcala Labs is one of the fastest-growing labs in the country. It was founded to react quickly to the needs of physicians and offer state-of-the-art, high-quality lab testing. In the realm of COVID, Alcala can administer these tests with a 98% accuracy rate (Antibody and PCR are 98% or higher).

Looking beyond COVID, Medivolve is building an infrastructure for future diagnostic, prevention, and treatment that has implications beyond the pandemic. The Collection Sites could be converted to test and treat a whole host of other diseases. Furthermore, as these sites remain operational, Medivolve is building an incredibly robust client list of more than 100,000 patient names. In other words, the company has spent very little to acquire these customers in terms of the customer acquisition cost. The company can then monetize this list by looking for new disruptive services and providing these to its customer base.

Medivolve Has Delivered Strong Returns and Technicals Continue to Look Good

The stock has formed a firm base on the five months of July 2020 to November 2020 as the stock price consolidated from $0.10 to $0.20. The stock started to make its move higher in the beginning of December on relatively much higher volume. Typically a high volume breakout through resistance is a strong bullish sign that a stock’s rally has legs. Since the bottom, Medivolve’s stock has surged to a high of $0.55 in mid-January 2021. This move represented a gain of approximately 500% from the consolidated base. From a technical perspective, the company’s consolidation and subsequent rise can be considered a “cup and handle” formation, a pretty popular signal in the realm of technical analysis.

Since then, the stock has seen a nice pullback and has been at the 50-day moving average support. If this support holds, this should make a good entry point for investors who use technical analysis to time their entry points. Looking at other technical indicators paints a bullish outlook for the company in the short, medium, and long term. The 50 Day Moving Average, 100 Day Moving Average, 200 Day Moving Average are aligned, confirming that the uptrend is still intact despite the recent pullback.

Other technical indicators, such as the MACD, are showing continued signs of strength as well. The MACD continues to be above the signal line showing positive momentum. Patient investors will need to wait for a bullish crossover before a “buy-signal” is given – but those who wait may also miss out on upside.

Medivolve Has a Strong Management Team Poised to Deliver

Medivolve is led by a high-quality and robust management team with track records of success in the healthcare space. With this strong management team, Medivolve is well-positioned to execute its plans and deliver strong long-term results to shareholders.

Douglas Sommerville — CEO, Director
Douglas has held prominent roles at pharmaceutical giants such as Teva Pharmaceuticals and Baxter Healthcare International. In this role as Head of Teva Canada, Mr. Sommerville was responsible for Teva’s third-largest global subsidiary, with sales above $1.3 billion. Douglas was also the Chairman of the Canadian Generic Pharmaceutical Association until he retired from Teva Canada in 2018. He holds an MBA from the Schulich School of Business.

Deborah Battiston — CFO
Deborah has over 25 years of financial management experience. She is on the Board of Directors at Savanna Capital Corp and was previously employed as a Chief Financial Officer by Q-Gold Resources.

Daniyal Baizak — Director
Daniyal is on the board of Medivolve, Inc. and Vice President-Corporate Development for African Gold Group, Inc. In the past, he held the position of President, Chief Executive Officer & Director at Routemaster Capital, Inc. Mr. Baizak received an undergraduate degree from Rotman School of Management. He has significant experience in finance and strategy, particularly on M&A, having worked on deals in the Central Asian and Russian markets.

Michael McCarthy — Strategic Advisor
Michael is widely recognized across Canada as a health care champion and advocate. As a principal with Grosso McCarthy, Mike has over 15 years of experience with the Ontario Ministry of Health and Long Term Care and over 25 years in health policy and delivery. In 2001, he was appointed Senior Policy Advisor to the Ontario Minister of Health. He has also been on the front lines of health care, working for 18 years as a psychiatric nurse.

Jim Rogers — Strategic Advisor
Jim co-founded the Quantum Fund, a global investment partnership. After retiring at age 37, Mr. Rogers continued to manage his portfolio and serve as a professor of finance at the Columbia University Graduate School of Business. Mr. Rogers also presciently saw the formation of the subprime mortgage crisis a year before it erupted.

Mike Mancias — Strategic Advisor
Mike has served as the Chief Performance Advisor to LeBron James for over 14 years and counting. His experience includes working with NBA, NFL, MLB, PGA, and top NCAA athletes. Mike attended the University of Texas Pan American and graduated with a degree in Health Education. He is licensed and nationally certified by the Accredited National Athletic Trainers Association and is a 14-year member of The National Basketball Athletic Trainers Association.

Disclaimer 

Digital Marketing Agency of Record: GloBull Technologies Inc., (“GloBull”). 

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 

2) The Article was issued on behalf of and sponsored by Medivolve Inc.. GloBull, has or expects to receive from Medivolve Inc.  VALUE OF COMPENSATION RECEIVED $92,000.00 for 30 DAYS days (24 BUSINESS DAYS). 

3) Statements and opinions expressed are the opinions of the author and not GloBull, its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by GloBull for this Article. GloBull was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. GloBull requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. GloBull, relies upon the authors to accurately provide this information and GloBull, has no means of verifying its accuracy. 

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to GloBull’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. GloBull does not render general or specific investment advice and the information on GloBull.com should not be considered a recommendation to buy or sell any security. GloBull, does not endorse or recommend the business, products, services, or securities of any company mentioned on GloBull.com. 

5) GloBull, and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Medivolve Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. 

These forward-looking statements include, among other things, statements relating to: 

(a) revenue generating potential with respect to Medivolve Inc.’s industry; 

(b) market opportunity;

(c) Medivolve Inc.’s business plans and strategies; 

(d) services that Medivolve Inc. intends to offer; 

(e) Medivolve Inc.’s milestone projections and targets;

(f) Medivolve Inc.’s expectations regarding receipt of approval for regulatory applications; 

(g) Medivolve Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and 

(h) Medivolve Inc.’s expectations regarding its ability to deliver shareholder value. 

Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: 

(a) the ability to raise any necessary additional capital on reasonable terms to execute Medivolve Inc.’s business plan;

(b) that general business and economic conditions will not change in a material adverse manner; 

(c) Medivolve Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; 

(d) Medivolve Inc.’s ability to enter into contractual arrangements with additional Pharmacies; 

(e) the accuracy of budgeted costs and expenditures; 

(f) Medivolve Inc.’s ability to attract and retain skilled personnel; 

(g) political and regulatory stability; 

(h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; 

(i) changes in applicable legislation; 

(j) stability in financial and capital markets; and 

(k) expectations regarding the level of disruption as a result of CV-19. 

Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance, or achievements of Medivolve Inc. to be materially different from any future plans, intentions, activities, results, performance, or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: 

(a) Medivolve Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; 

(b) public health crises such as CV-19 may adversely impact Medivolve Inc.’s business; 

(c) the volatility of global capital markets; 

(d) political instability and changes to the regulations governing Medivolve Inc.’s business operations 

(e) Medivolve Inc. may be unable to implement its growth strategy; and 

(f) increased competition. 

Except as required by law, Medivolve Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Medivolve Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency, or completeness of the information in this document. Neither Medivolve Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Medivolve Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Medivolve Inc. or such entities and are not necessarily indicative of future performance of Medivolve Inc. or such entities.

Caution: Microcap stocks are not suitable for everyone, and it’s important to carefully consider your own financial goals and risk tolerance before making any investment decisions. We recommend consulting a licensed investment professional.